Results 241 to 250 of about 2,724,657 (277)

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study.

Am J Nephrol
Hamano T, Koiwa F, Isaka Y, Yokoyama K, Fukagawa M, Inagaki Y, Watanabe YS, Honda D, Akizawa T.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study.

American Journal of Kidney Diseases, 2020
RATIONALE & OBJECTIVE Although multiple lines of evidence suggest a negative impact of secondary hyperparathyroidism on patients with kidney failure treated by hemodialysis, it is uncertain whether patients can detect associated symptoms.
A. Levy, S. Xing, S. Brunelli, K. Cooper, F. Finkelstein, M. Germain, M. Kimel, R. Platt, V. Belozeroff   +8 more
semanticscholar   +1 more source

Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment

Therapeutic apheresis and dialysis, 2018
The classic pathogenesis of secondary hyperparathyroidism (SHPT) began with the trade‐off hypothesis based on parathyroid hormone hypersecretion brought about by renal failure resulting from a physiological response to correct metabolic disorder of ...
Masahide Mizobuchi, H. Ogata, F. Koiwa
semanticscholar   +1 more source

The Importance of Adherence in the Treatment of Secondary Hyperparathyroidism

Blood Purification, 2018
Secondary hyperparathyroidism (SHPT) is a frequent condition in the presence of chronic kidney disease (CKD). In CKD patients, SHPT is reported to increase both morbidity and mortality, especially cardiovascular.
C. Alfieri, A. Regalia, F. Zanoni, S. Vettoretti, M. Cozzolino, P. Messa   +5 more
semanticscholar   +1 more source

Secondary Hyperparathyroidism

DeckerMed Complex General Surgical Oncology, 2019
Secondary hyperparathyroidism is defined and its pathophysiology, delineated. Key components of the diagnostic work-up, medical management, and indications for surgery are described.
Anna C. Beck, S. Sugg
semanticscholar   +1 more source

Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease

American Journal of Nephrology, 2016
Background/Aims: Vitamin D insufficiency and secondary hyperparathyroidism (SHPT) are associated with increased morbidity and mortality in chronic kidney disease (CKD) and are poorly addressed by current treatments. The present clinical studies evaluated
S. Sprague, P. Crawford, J. Melnick, S. Strugnell, Shaukat Ali, R. Mangoo‐Karim, Sungchun Lee, P. Petkovich, C. Bishop   +8 more
semanticscholar   +1 more source

Long‐term hypovitaminosis D and secondary hyperparathyroidism outcomes of the Roux‐en‐Y gastric bypass: a systematic review

Obesity Reviews, 2017
Pre‐operative Vitamin D deficiency is markedly prevalent in prospective bariatric surgery patients. While bariatric surgery leads to significant weight loss, it can exacerbate or prolong Vitamin D deficiency.
Noah J. Switzer, G. Marcil, S. Prasad, E. Debru, N. Church, P. Mitchell, E. Billington, Richdeep Gill   +7 more
semanticscholar   +1 more source

Efficacy and safety of ultrasound‐guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease

Head and Neck, 2017
The purpose of this study was to determine if ultrasound‐guided radiofrequency ablation (RFA) of hyperplastic parathyroid glands could be used to treat secondary hyperparathyroidism (HPT) in patients with chronic kidney disease.
C. Peng, Zhengxian Zhang, Ji-Bin Liu, Hongyu Chen, Xiao Tu, Rihong Hu, J. Ni, Ning Weng, H. Pang, Zhengmei Xue   +9 more
semanticscholar   +1 more source